What Nabla Bio does
Nabla Bio is a Cambridge, Massachusetts–based AI-for-science company focused on de novo protein (primarily antibody) design for therapeutic discovery. The company positions its approach as a “designable” alternative to trial-and-error drug discovery by combining generative protein modeling with tightly integrated, human-relevant wet-lab testing.
More
Its platform centers on JAM, a multimodal generative system that can take partial molecular context (such as a disease target or epitope) and “autocomplete” remaining design elements to produce candidate biologics with binding and developability properties. Nabla also emphasizes epitope-precise design, parallel design campaigns (designing many targets at once), and the generation of developable multispecific architectures. In addition to designing and optimizing candidates for partners’ pipelines, Nabla describes a business model that includes partnering/licensing of designed molecules and embedding its platform into partner discovery workflows. The company is backed by venture investors and has announced research collaborations with large pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, and Takeda.